throbber
(19) United States
`(12) Patent Application Publication (10) Pub. No.: US 2011/0082145 A1
`
` Schneider et al. (43) Pub. Date: Apr. 7, 201 1
`
`
`US 20110082145A1
`
`(54) OLOPATADINE COMPOSITIONS AND USES
`THEREOF
`
`(75)
`
`Inventors:
`
`_
`L. Wayne Schneider, Crowley, TX
`(US); Wesley Wehsin Han,
`Arlington, TX (US); Masood A.
`Chowhan, Arlington, TX (US)
`
`(73) Assignee:
`
`ALCON RESEARCH, LTD., Fort
`Worth, TX (US)
`
`(21) Appl. No.:
`
`12/896,056
`
`(22)
`
`Filed:
`
`Oct. 1, 2010
`
`Related US. Application Data
`(60) Provisional application No. 61/247,618, filed on Oct.
`1, 2009.
`
`Publication Classification
`
`(51)
`
`Int. Cl.
`A61K 31/53 77
`A61K 31/496
`A61P 37/08
`A61P 29/00
`A6IP 27/02
`
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`
`(2006.01)
`A6IP 27/00
`(2006.01)
`A6IP 1 7/00
`(52) US. Cl. ................................. 514/235.2; 514/253.07
`
`(57)
`
`ABSTRACT
`.
`.
`.
`.
`.
`.
`.
`.
`The invention prov1des solution compos1tions comprismg
`olopatadine and a PDE4 inhibitor compound of Formula I:
`
`(Formula I)
`
`R1\0
`
`O
`
`R2/
`
`0
`
`R19-
`
`R14
`
`Ill
`
`/
`
`R5
`|
`R6
`
`The invention also provides methods for treating allergic and
`inflammatory diseases. More particularly, the present inven-
`tion relates to formulations of olopatadine and their use for
`treating and/or preventing allergic or inflammatory disorders
`of the eye, nose, skin, and ear.
`
`|PR2018—01020 and |PR2018-01021, Exhibit 1006, Page 1
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1006, Page 1
`
`

`

`Patent Application Publication
`
`Apr. 7, 2011 Sheet 1 of 2
`
`US 2011/0082145 A1
`
`
`
`
`
`OiapatadineFreeBaseGene“("inwlv)
`
`Pint of Oiopataaiine Free Base Saiubility versus PDE4 inhibitor
`Cnneentratian (% WM}.
`
`mnmd‘iafipHHACmFWTWMmeomdmm
`y : {3,2857x + {11828
`y 2 {3,2347% + {3.2806
`, 0‘3292x + 0.2005
`G 7 \\\\\\\\\\\\\\7\\\\\\\\\\
`‘Fi? =93Q§3Q~ “9%
`R2 -”-
`‘1
`
`
`
`
`
`5ch-
`
`{M
`
`{732
`
`9.3
`
`0.4
`
`0.5
`
`(3.63
`
`0]
`
`
`
`
`093
`1.9
`1.1
`“:2
`
`0.8
`
`F’Dfié Enhibitm fiancefitrafiian (”fa wlv}
`
`FIG? 1.
`
`|PR2018—01020 and |PR2018-01021, Exhibit 1006, Page 2
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1006, Page 2
`
`

`

`Patent Application Publication
`
`Apr. 7, 2011 Sheet 2 of 2
`
`US 2011/0082145 A1
`
`Plot 0f Olcpatadine Free Base Salubility versus PDE4 Inhibitor Cementration
`(mifliMoiar).
`
`
`
`y = 0.5087): + 5.9411
`GlopamdineFmeBaseGena.{mm E3
`
`
`
`
`‘4
`a.
`U1
`r.::
`.4
`U7
`8 91011121314fi51fi17181926
`[KS
`(.55
`
`;
`
`PDE4 inhibimr concentration (mM)
`
`“FIG. 2
`
`|PR2018—01020 and |PR2018—01021, Exhibit 1006, Page 3
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1006, Page 3
`
`

`

`US 2011/0082145 A1
`
`Apr. 7, 2011
`
`OLOPATADINE COMPOSITIONS AND USES
`THEREOF
`
`CROSS-REFERENCE TO RELATED
`APPLICATION
`
`[0001] This application claims priority under 35 U.S.C.
`§119 to US. Provisional Patent Application No. 61/247,618
`filed Oct. 1, 2009, the entire contents of which are incorpo-
`rated herein by reference.
`
`FIELD OF THE INVENTION
`
`[0002] The present invention relates to olopatadine formu-
`lations used for treating allergic and inflammatory diseases.
`More particularly, the present invention relates to formula-
`tions of olopatadine and their use for treating and/or prevent-
`ing allergic or inflammatory disorders of the eye, ear, skin,
`and nose.
`
`BACKGROUND OF THE INVENTION
`
`[0003] As taught in US. Pat. Nos. 4,871,865 and 4,923,
`892, both assigned to Burroughs Wellcome Co. (“the Bur-
`roughs Wellcome patents”), certain carboxylic acid deriva-
`tives of doxepin,
`including olopatadine (chemical name:
`Z-l 1-(3-dimethylaminopropylidene)-6, 1 1 -dihydrodibenz[b,
`e]oxepine-2-acetic acid), have antihistamine and antiasth-
`matic activity. These two patents classify the carboxylic acid
`derivatives of doxepin as mast cell stabilizers with antihista-
`minic action because they are believed to inhibit the release of
`autacoids (i.e., histamine, serotonin, and the like) from mast
`cells and to inhibit directly histamine’s effects on target tis-
`sues, The Burroughs Wellcome patents teach various phar-
`maceutical
`formulations containing the carboxylic acid
`derivatives of doxepin, including nasal spray and ophthalmic
`formulations. See, for example, Col. 7,
`lines 7-26, and
`Examples 8 (H) and 8 (I) of the ’865 patent.
`[0004] US. Pat. No. 5,116,863, assigned to Kyowa Hakko
`Kogyo Co., Ltd., (“the Kyowa patent”), teaches that acetic
`acid derivatives of doxepin and, in particular, olopatadine,
`have anti-allergic and anti-inflammatory activity. Medica-
`ment forms taught by the Kyowa patent for the acetic acid
`derivatives of doxepin include a wide range of acceptable
`carriers; however, only oral and injection administration
`forms are mentioned.
`
`[0005] US. Pat. No. 5,641,805, assigned to Alcon Labora-
`tories, Inc. and Kyowa Hakko Kogyo Co., Ltd., teaches topi-
`cal ophthalmic formulations containing olopatadine for treat-
`ing allergic eye diseases. According to the ’805 patent, the
`topical formulations may be solutions, suspensions or gels.
`The formulations contain olopatadine, an isotonic agent, and
`“if required, a preservative, a buffering agent, a stabilizer, a
`viscous vehicle and the like.” See Col. 6, lines 30-43. “[P]
`olyvinyl alcohol, polyvinylpyrrolidone, polyacrylic acid or
`the like” are mentioned as the viscous vehicle. See Col. 6,
`lines 55-57.
`
`Phosphodiesterase type-IV (PDE4 or PDE-IV) is
`[0006]
`the predominant cyclic nucleotide hydrolyzing enzyme found
`in inflammatory leukocytes, such as mast cells, neutrophils,
`monocytes and T—lymphocytes. PDE4 inhibitor compounds
`are known to be useful as anti-inflammatory and anti-allergy
`agents.
`In general, it is more desirable for active ingredients
`[0007]
`to be in solution rather than suspension in a pharmaceutical
`composition. For instance, solutions are easier to manufac-
`
`ture, easier to handle, provide better penetration to a target
`site of action, and provide better dosage consistency.
`[0008] A formulation comprising both olopatadine and
`PDE4 inhibitor compounds is desirable because the combi-
`nation addresses both the early and late phases of the allergic
`response. In addition, a formulation comprising compounds
`that enhance the solubility of olopatadine is desirable,
`because it assures that the olopatadine will not precipitate
`during a desired shelf life, and allows for an increased con-
`centration of solubilized olopatadine.
`
`SUMMARY OF THE INVENTION
`
`[0009] The invention provides pharmaceutical aqueous
`solution compositions comprising olopatadine and a PDE4
`inhibitor compound of Formula I, as provided herein. The
`invention also provides methods for treating allergic and
`inflammatory conditions ofthe eye, ear, skin, and nose. In one
`aspect, the concentration of olopatadine is at least 0.17% w/v,
`and the concentration of the PDE4 inhibitor compound of
`Formula I is at least 0.05% w/v in a solution composition.
`[0010]
`Specific preferred embodiments of the invention
`will become evident from the following more detailed
`description of certain preferred embodiments and the claims.
`
`BRIEF DESCRIPTION OF THE DRAWINGS
`
`FIG. 1 is a graph showing Olopatadine Free Base
`[0011]
`Solubility versus PDE4 Inhibitor Concentration (% w/v).
`[0012]
`FIG. 2 is a graph showing Olopatadine Free Base
`Solubility versus PDE4 Inhibitor Concentration (milliMo-
`lar).
`
`DETAILED DESCRIPTION OF THE INVENTION
`
`[0013] The particulars shown herein are by way of example
`and for purposes of illustrative discussion of the preferred
`embodiments of the present invention only and are presented
`in the cause of providing what is believed to be the most
`useful and readily understood description of the principles
`and conceptual aspects of various embodiments of the inven-
`tion. In this regard, no attempt is made to show structural
`details ofthe invention in more detail than is necessary for the
`fundamental understanding of the invention, the description
`taken with the drawings and/or examples making apparent to
`those skilled in the art how the several forms of the invention
`
`may be embodied in practice.
`[0014] As used herein and unless otherwise indicated, the
`terms “a” and “an” are taken to mean “one”, “at least One” or
`“one or more”. Unless otherwise required by context, singu-
`lar terms used herein shall include pluralities and plural terms
`shall include the singular.
`[0015] Unless indicated otherwise, all component amounts
`provided herein are presented on a % (w/v) basis and all
`references to olopatadine are to olopatadine free base.
`[0016]
`In certain embodiments,
`the invention provides
`solution compositions comprising a therapeutically effective
`amount of olopatadine and a PDE4 inhibitor compound of
`Formula I that enhances the aqueous solubility of approxi-
`mately 0.2-0.6% olopatadine.
`
`|PR2018-01020 and |PR2018-01021, Exhibit 1006, Page 4
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1006, Page 4
`
`

`

`US 2011/0082145 A1
`
`Apr. 7, 2011
`
`[0017] The term “therapeutically effective amount” refers
`to the amount of a solution composition of the invention,
`olopatadine, or a PDE4 inhibitor compound of Formula I
`determined to produce a therapeutic response in a mammal.
`Such therapeutically effective amounts are readily ascer-
`tained by one of ordinary skill in the art and using methods as
`described herein.
`
`[0018] The terms “pharmaceutical aqueous solution com-
`position” and “solution composition” as used herein refer to a
`composition comprising olopatadine or a pharmaceutically
`acceptable salt thereof, a PDE4 inhibitor compound of For-
`mula I or a pharmaceutically acceptable salt thereof, and a
`pharmaceutically acceptable carrier (such as an ophthalmo-
`logic or nasal or otic carrier, or carrier suitable for delivery to
`the skin), excipient, or diluent as described herein that is
`capable of inducing a desired therapeutic effect (e.g. reduc-
`ing, preventing, and/or eliminating allergies or allergy symp-
`toms or inflammation) when properly administered to a
`patient. As used herein, the terms “pharmaceutical aqueous
`solution composition” and “solution composition” include
`compositions in which olopatadine (or a pharmaceutically
`acceptable salt thereof) and a PDE4 inhibitor compound of
`Formula I (or a pharmaceutically acceptable salt) are in solu-
`tion, and wherein the overall composition is a solution, sus-
`pension, or semi-solid (for example cream, gel, or emulsion),
`depending on the presence or absence of any excipients in the
`composition.
`[0019] As used herein, the term “pharmaceutically accept-
`able ophthalmologic or nasal or otic carrier” refers to those
`carriers that cause at most, little to no ocular, otic, or nasal
`irritation, provide suitable preservation if needed, and deliver
`olopatadine and a compound of Formula I in a homogenous
`dosage.
`[0020] As used herein, the term “patient” includes human
`and animal subjects.
`[0021]
`In one embodiment, a solution composition of the
`invention comprises a PDE4 inhibitor compound having
`structural Formula I:
`
`heteroaryl, heteroaralkyl, and hydroxyalkyl, any of
`which may be optionally substituted;
`[0024]
`sis 1-8;
`[0025] G1 is selected from the group consisting of
`alkoxy, amino, amido, carbonyl, hydroxy, ether, an
`amino acid, and null;
`[0026] G2 is selected from the group consisting of alkyl,
`alkoxy, amino, aryl, halo, haloalkyl, heterocycloalkyl,
`heteroaryl, carboxylalkylamino, guanidine, an amino
`acid, and null, any of which may be optionally substi-
`tuted;
`[0027] G3 is selected from the group consisting of alkyl,
`alkoxy, amino, hydroxy, ether, carboxyl, hydroxamic
`acid, an amino acid, phosphonate, phosphoamide, and
`null, any of which may be optionally substituted;
`[0028]
`R5 is selected from the group consisting of
`7(CR8R9)MW(CR10R“)M7 and 7(CR12R13)P7;
`[0029] W is selected from the group consisting of O,
`N(R7), C(O)N(R7), and SOq;
`[0030] m, n, and q are independently 0, l or 2;
`[0031]
`p is l or 2;
`[0032]
`R6 is selected from the group consisting of car-
`boxyl, alkylcarboxy, amido, aryl, heteroaryl, cycloalkyl,
`heterocycloalkyl, alkyl, heteroalkyl, acyl, and hydrox-
`amic acid, any of which may be optionally substituted;
`[0033]
`R7 and R14 are independently selected from the
`group consisting of hydrogen, halogen, hydroxyl, lower
`alkyl, hydroxyalkyl, haloalkyl, and aminoalkyl;
`[0034] R8, R9, R10, R11, R12 and R13 are independently
`selected from the group consisting of hydrogen and
`optionally substituted lower alkyl;
`[0035]
`and R19 is selected from the group consisting of
`hydrogen, halogen, lower alkyl and haloalkyl; and
`[0036]
`a pharmaceutically acceptable carrier or
`excipient.
`In one embodiment, the PDE4 inhibitor compound
`[0037]
`of Formula I is (4-(3,5-Dichloropyridin-4-ylamino)-7-meth-
`oxy-8-(6-(4-methylpiperazin-l -yl)hexyloxy)quinolin-2
`(lH)-one):
`
`(Formula I)
`
`N
`
`EN]
`
`R14
`|
`N
`
`0
`
`/
`
`R19.
`
`R5
`
`|R
`
`6
`
`R1
`
`\0
`
`O
`
`R2/
`
`[0022]
`
`In certain embodiments:
`
`R1 and R2 are independently selected from the
`[0023]
`group consisting of 7(CH2)SG1G2G3, acyl, acylalkyl,
`carboxyalkyl, cyanoalkyl, alkoxy, alkoxyalkyl, ami-
`doalkyl, amino, alkyl, alkylalkoxy, aminoalkyl, alkenyl,
`alkynyl, carboxyl, carboxyalkyl, ether, heteroalkyl,
`haloalkyl,
`cycloalkyl,
`cycloalkylalkyl,
`heterocy-
`cloalkyl, heterocycloalkylalkyl, aralkyl, aryl, guanidine,
`
`|PR2018—01020 and |PR2018—01021, Exhibit 1006, Page 5
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1006, Page 5
`
`

`

`US 2011/0082145 A1
`
`Apr. 7, 2011
`
`including but not limited to surfactants, tonicity agents, buff-
`ers, preservatives, and viscosity building agents.
`[0044] An appropriate buffer system (e.g., sodium phos-
`phate, sodium acetate, sodium citrate, sodium borate or boric
`acid) may be added to the compositions to prevent pH drift
`under storage conditions. The particular concentration will
`vary, depending on the agent employed. Preferably, however,
`the buffer will be chosen to maintain a target pH within the
`range of pH 6.0-7.5.
`[0045]
`In certain embodiments, the concentration of olo-
`patadine in a solution composition of the invention is at least
`0.05% w/v. For example, the concentration of olopatadine
`can be about 0.05%, 0.075%, 0.10%, 0.15%, 0.20%, 0.25%,
`0.30%, 0.35%, 0.40%, 0.45%, 0.50%, 0.55%, or 0.60% w/v,
`or higher. In certain embodiments, a solution composition of
`the invention is a solution formulation that contains at least
`
`0.05% w/v olopatadine. In certain embodiments, solution
`formulations ofthe present invention contain 0.17-0.62% w/v
`olopatadine. In certain embodiments, solution formulations
`intended for use in the eye contain 0.17-0.25% olopatadine,
`and preferably 0.18-0.22% w/v olopatadine.
`In certain
`embodiments, solution formulations intended for use in the
`nose contain 0.38-0.62% w/v olopatadine.
`[0046]
`In certain embodiments,
`the concentration of a
`PDE4 inhibitor compound of Formula I in a solution compo-
`sition of the invention is at least 0.05% w/v. For example, the
`concentration of a PDE4 inhibitor compound of Formula I
`can be about 0.05%, 0.10%, 0.15%, 0.20%, 0.25%, 0.30%,
`0.35%, 0.40%, 0.45%, 0.50%, 0.55%, or 0.60% w/v, or
`higher.
`In certain embodiments, solution compositions of
`[0047]
`the invention are useful for treating allergic or inflammatory
`disorders, including allergic or inflammatory disorders ofthe
`eye, nose, skin, and ear.
`[0048]
`In certain embodiments, an ophthalmic formulation
`is administered to the cyc of a patient in need thereof to treat
`an ocular disorder. The term “ocular disorder” as used herein
`
`includes allergic and/or inflammatory conditions of the eye,
`such as ophthalmic allergic disorders, including allergic con-
`junctivitis, vernal conjunctivitis, vernal keratoconjunctivitis,
`and giant papillary conjunctivitis, dry eye, glaucoma, corneal
`neovascularization, optic neuritis, Sjogren’s syndrome, reti-
`nal ganglion degeneration, ocular ischemia, retinitis, retino-
`pathies, uveitis, ocular photophobia, and of inflammation and
`pain associated with acute injury to the eye tissue. Specifi-
`cally, the compounds may be used to treat glaucomatous
`retinopathy and/or diabetic retinopathy. The compounds may
`also be used to treat post-operative inflammation or pain as
`from ophthalmic surgery such as cataract surgery and refrac-
`tive surgery. In certain embodiments, the compounds of the
`present invention are used to treat an allergic eye disease
`selected from the group consisting of allergic conjunctivitis;
`vernal conjunctivitis; vernal keratoconjunctivitis; and giant
`papillary conjunctivitis. allergic conjunctivitis.
`[0049]
`In one embodiment, a solution composition of the
`invention is an ophthalmic formulation for delivery to the eye,
`such as a topical ophthalmic formulation. The solution com-
`position may comprise ophthalmologically acceptable pre-
`servatives,
`surfactants, viscosity enhancers, penetration
`enhancers, buffers, tonicity agents, and water to form an
`aqueous, sterile ophthalmic solution, suspension, or emul-
`sion. Gelling agents can also be used, including, but not
`limited to, gellan and xanthan gum. In order to prepare sterile
`ophthalmic ointment formulations, olopatadine and a PDE4
`
`In another embodiment, the compound of Formula I
`[0038]
`(4-(3,5-Dichloropyridin-4-ylamino)-7-methoxy-8-(6-
`is
`morpholinohexyloxy)quinolin-2(1H)-one):
`
`O Q
`
`[0039] These compounds, and other PDE4 inhibitor com-
`pounds of Formula I, are PDEIV inhibitors, and are described
`in detail in co-pending US. application Ser. No. 11/774,053
`filed Jul. 6, 2007, and U.S. application Ser. No. 12/544,185
`filedAug. 19, 2009, the disclosures ofwhich are incorporated
`by reference in their entirety.
`[0040] Olopatadine is a known compound that can be
`obtained by the methods disclosed in US. Pat.No. 5,116,863,
`the entire contents of which are hereby incorporated by ref-
`erence in the present specification.
`[0041] Generally, olopatadine will be added in the form of
`a pharmaceutically acceptable salt. Examples of the pharma-
`ceutically acceptable salts of olopatadine include inorganic
`acid salts such as hydrochloride, hydrobromide, sulfate and
`phosphate; organic acid salts such as acetate, maleate, fuma-
`rate, tartrate and citrate; alkali metal salts such as sodium salt
`and potassium salt; alkaline earth metal salts such as magne-
`sium salt and calcium salt; metal salts such as aluminum salt
`and zinc salt; and organic amine addition salts such as triethy-
`lamine addition salt (also known as tromethamine), morpho-
`line addition salt and piperidine addition salt. The most pre-
`ferred form of olopatadine for use in the
`solution
`compositions of the present invention is the hydrochloride
`salt of
`(Z)-1 1-(3-dimethylaminopropylidene)-6,11-dihy-
`drodibenz-[b,e]oxepin-2-acetic acid. When olopatadine is
`added to the compositions of the present invention in this salt
`form, 0.222% olopatadine hydrochloride is equivalent to
`0.2% olopatadine free base, 0.443% olopatadine hydrochlo-
`ride is equivalent to 0.4% olopatadine free base, and 0.665%
`olopatadine hydrochloride is equivalent to 0.6% olopatadine
`free base. As used herein, reference to a concentration of
`olopatadine refers to olopatadine free base concentration,
`unless otherwise specified.
`[0042] The PDE4 inhibitor compounds of Formula I have
`been unexpectedly found to increase the solubility of olopata-
`dine. Thus, an aqueous solution composition of the present
`invention can be prepared without the need for any other
`solubility enhancing components.
`[0043] The compositions administered according to the
`present invention may also include various other ingredients,
`
`|PR2018—01020 and |PR2018—01021, Exhibit 1006, Page 6
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1006, Page 6
`
`

`

`US 2011/0082145 A1
`
`Apr. 7, 2011
`
`inhibitor compound of Formula I are combined with a pre-
`servative in an appropriate vehicle. Sterile ophthalmic gel
`formulations may be prepared by suspending olopatadine and
`a PDE4 inhibitor compound of Formula I in a hydrophilic
`base prepared from the combination of, for example, CAR-
`BOPOL®-974, CARBOPOL®-940 (BF Goodrich, Char-
`lotte, N.C.), or the like, according to the published formula-
`tions for analogous ophthalmic preparations; preservatives
`and tonicity agents can be incorporated.
`[0050]
`Solution compositions of the invention can be
`administered topically to the eye, for example, to treat allergic
`conjunctivitis and/or ocular inflammation. In general, the
`doses used for the above described purposes will vary, but will
`be in an effective amount to reduce or eliminate allergic
`conjunctivitis and/or ocular inflammation. Generally, 1-2
`drops of such compositions will be administered one or more
`times per day. For example, the composition can be adminis-
`tered 2 to 3 times a day or as directed by an eye care provider.
`[0051] Topical ophthalmic products may also be packaged
`in multidose form. Preservatives may thus be required to
`prevent microbial contamination during use. Suitable preser-
`vatives include: benzalkonium chloride, benzododecinium
`bromide, chlorobutanol, methyl paraben, propyl paraben,
`phenylethyl
`alcohol,
`edetate
`disodium,
`sorbic
`acid,
`polyquatemium-l, or other agents known to those skilled in
`the art. Such preservatives are typically employed at a level of
`from 0.001 to 5.0% w/v. Unit dose compositions of the
`present invention will be sterile, but typically unpreserved.
`Such compositions, therefore, generally will not contain pre-
`servatives. The ophthalmic compositions of the present
`invention may also be provided preservative free and pack-
`aged in unit dose form.
`[0052] The compositions of the present invention option-
`ally comprise one or more excipients. Excipients commonly
`used in solution compositions intended for topical application
`to the eyes or nose, such as solutions or sprays, include, but
`are not limited to, tonicity agents, preservatives, chelating
`agents, buffering agents, surfactants and antioxidants. Suit-
`able tonicity-adjusting agents include mannitol, sodium chlo-
`ride, glycerin, sorbitol and the like. Suitable preservatives
`include p-hydroxybenzoic acid ester, benzalkonium chloride,
`benzododecinium bromide, polyquatemium-l and the like.
`Suitable chelating agents include sodium edetate and the like.
`Suitable buffering agents include phosphates, borates, cit-
`rates, acetates, tromethamine, and the like. Suitable surfac-
`tants include ionic and nonionic surfactants, though nonionic
`surfactants are preferred, such as polysorbates, polyethoxy-
`lated castor oil derivatives, polyethoxylated fatty acids, poly-
`ethoxylated alcohols, polyoxyethylene-polyoxypropylene
`block copolymers, and oxyethylated tertiary octylphenol
`formaldehyde polymer (tyloxapol). Suitable antioxidants
`include sulfites, thiosulfate, ascorbates, BHA, BHT, toco-
`pherols, and the like. The compositions of the present inven-
`tion optionally comprise an additional active agent. The com-
`positions of the present invention may contain one or more
`nonionic, anionic, or cationic polymers as lubricants or as
`viscosity agents, including but not limited to hydroxypropyl
`methylcelluloses (HPMCs), methylcelluloses, carboxymeth-
`ylcelluloses (CMCs), polyethylene glycols (PEGs), polox-
`amers, polypropylene glycols, xanthan gums, guar gums,
`carbomers, polyvinyl alcohols (PVAs), polyvinylpyrroli-
`dones (PVPs), alginic acids and salts, gellan gums, carrag-
`eenans, and chitosans.
`
`[0053] Various tonicity agents may be employed to adjust
`the tonicity of the composition, preferably to that of natural
`tears for ophthalmic compositions. For example, sodium
`chloride, potassium chloride, magnesium chloride, calcium
`chloride, dextrose, mannitol, sorbitol, propylene glycol, or
`glycerol may be added to the composition to approximate
`physiological tonicity. Such an amount of tonicity agent will
`vary, depending on the particular agent to be added. In gen-
`eral, however, the compositions will have a tonicity agent in
`an amount suflicient to cause the final composition to have an
`ophthalmically acceptable osmolality (generally about 150-
`450 mOsm, preferably 250-350 mOsm).
`[0054]
`In certain embodiments, a composition ofthe inven-
`tion has a pH of about 3 .0 to about 8.5. In one embodiment, an
`ophthalmic composition of the present invention has a pH of
`4.0-8.0, preferably a pH of5.0-7.5, and most preferably a pH
`of 6.0-7.4. Compositions ofthe present invention intended for
`use in the nose preferably have a pH of 3.0-8.0 and most
`preferably a pH of 50-75.
`[0055]
`In certain embodiments, a solution composition of
`the invention can be formulated for nasal applications, and
`can be used to treat nasal disorders. Thus, in certain embodi-
`ments, the invention provides methods for treating a nasal
`disorder, comprising administering a solution composition of
`the invention to the nose of a patient in need thereof. The term
`“nasal disorder” as used herein includes allergic and/or
`inflammatory conditions of the nose.
`[0056]
`In a further embodiment, nasal solution composi-
`tions of the invention are formulated to provide for a thera-
`peutically effective intranasal concentration. For example, a
`nasal solution composition of the invention may have an
`intranasal concentration of about 0.1-1000 nM or 1-100 nM.
`
`Intranasal compositions are delivered to the nasal mucosa one
`to four times per day according to the routine discretion of a
`skilled clinician. The pH of the formulation should range
`from 3 to 8 or preferably from 5 to 7.5. Topical administration
`directly onto the nasal mucosa via an intranasal insert or
`implant device or a solution drug-delivery-sponge (GEL-
`FOAM®, Pharmacia & Upjohn, Kalamazoo, Mich.) may
`deliver olopatadine and a PDE4 inhibitor compound of For-
`mula I at the rate of 1-2 [Ll/hour (e.g. 0.0001-10 mg/day) for
`several weeks according to the device design, its drug release
`characteristics, and according to the discretion of a skilled
`clinician.
`
`[0057] While the precise regimen is left to the discretion of
`the clinician, the resulting solution or solutions are preferably
`administered intranasally as described herein one to four
`times a day, or as directed by the clinician.
`[0058] A nasally acceptable carrier refers to those carriers
`that cause at most, little to no nasal irritation, provide suitable
`preservation if needed, and deliver a solution composition of
`the present invention in a homogenous dosage. For nasal
`delivery; a solution composition of the invention may be
`combined with nasally acceptable preservatives, co-solvents,
`surfactants, viscosity enhancers, penetration enhancers, buff-
`ers, tonicity agents, and water to form an aqueous, sterile
`suspension, solution, emulsion, or viscous, semi-viscous, or
`semi-solid gels. Nasal solution formulations may be prepared
`by dissolving the agent in a physiologically acceptable iso-
`tonic aqueous buffer. Further, the nasal solution may include
`a nasally acceptable surfactant. Viscosity building com-
`pounds, such as hydroxymethyl cellulose, hydroxyethyl cel-
`lulose, methylcellulose, or carbomers, for example, may be
`
`|PR2018—01020 and |PR2018-01021, Exhibit 1006, Page 7
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1006, Page 7
`
`

`

`US 2011/0082145 A1
`
`Apr. 7, 2011
`
`added to the compositions ofthe present invention to improve
`the retention of the compounds.
`[0059]
`In order to prepare a sterile nasal ointment formu-
`lation, a solution composition of the invention may comprise
`a preservative in an appropriate vehicle. Sterile nasal gel
`formulations may be prepared by suspending olopatadine
`and/or the PDE4 inhibitor compound of Formula I in a hydro-
`philic base prepared from, for example, CARBOPOL®-974,
`CARBOPOL®-940 (BF Goodrich, Charlotte, NC), or the
`like, according to methods known in the art for other suitable
`nasal formulations. VISCOAT® (Alcon Laboratories, Inc.,
`Fort Worth, Tex.) may be used for intranasal injection, for
`example. Other compositions of the present invention may
`contain penetration enhancing materials such as CREMO-
`PHOR® (Polyoxyethylene castor oil) and TWEEN® 80
`(polyoxyethylene sorbitan monolaureate).
`[0060] The compositions of the invention can be adminis-
`tered intranasally in the form of a nasal spray, as is known to
`those skilled in the art.
`
`[0061] Nasal delivery may be achieved by incorporation of
`olopatadine and the PDE4 inhibitor compound of Formula I
`into bioadhesive particulate carriers (<200 um) such as those
`comprising cellulose, polyacrylate or polycarbophil, in con-
`junction with suitable absorption enhancers such as phospho-
`lipids or acylcarnitines. Available systems include those
`developed by DanBiosyst and Scios. The formulation can be
`administeredusing a simple nasal spray device available from
`companies such as Valois or Pfeiffer.
`[0062]
`In certain embodiments, a solution composition
`comprising olopatadine and a PDE4 inhibitor compound of
`Formula I is formulated for delivery to the skin. Particularly
`compositions intended for application to the skin can be solu-
`tion, suspension or semisolid. However, the olopatadine (or
`pharmaceutically acceptable salt thereof) and PDE4 inhibitor
`compound (or pharmaceutically acceptable salt thereof) pre-
`sented in the said dosage forms should be all molecularly
`dissolved as a solution. The excipients presented in the dos-
`age forms can be solid as a suspension or semisolid as a
`cream, for example. The viscosity of the said compositions
`can be variant from 1 to 100,000 cps or higher depending on
`the needs of the dermatological product.
`[0063]
`In a further embodiment, otic compositions com-
`prising olopatadine and a PDE4 inhibitor compound of For-
`mula I are formulated to provide for a pharmacologically
`effective intraotic concentration. Topical otic compositions
`may be delivered to the ear one to four or more times, per day
`according to the routine discretion of a skilled clinician. The
`pH of the formulation should range from 4.0 to 9.0, or from
`4.5 to 7.4. Topical administration directly onto the otic nerves
`(auditory and vestibular) and/or otic nerve-heads via an
`intraotic insert or implant device or a solution drug-delivery-
`sponge (GELFOAM®, Pharmacia & Upjohn, Kalamazoo,
`Mich.) may deliver a solution composition of the invention at
`the rate of 1-2 [Ll/hour (e.g. 0.0001-10 mg/day) for several
`weeks according to the device design, its drug release char-
`acteristics, and according to the discretion of a skilled clini-
`c1an.
`
`For otic delivery, a solution composition of the
`[0064]
`invention may be combined with otically acceptable preser-
`vatives, co-solvents, surfactants, viscosity enhancers, pen-
`etration enhancers, buffers, tonicity agents, or water to form
`an aqueous, sterile suspension, solution, or viscous, semi-
`viscous, or semi-solid gels.
`
`Solution compositions of the present invention may
`[0065]
`be delivered directly to the ear (for example: topical otic drops
`or ointments; slow release devices in the ear or implanted
`adjacent to the ear). Local administration includes otic intra-
`muscular, intratympanic cavity and intracochlear injection
`routes of administration. Furthermore, a solution composi-
`tion of the invention can be administered to the inner ear by
`placement of a gelfoam, or similar absorbent and adherent
`product, soaked with a solution composition of the invention
`against the window membrane of the middle/inner ear or
`adjacent structure with due discretion and caution by a skilled
`clinician.
`
`[0066] The compositions of the present invention are pref-
`erably packaged in opaque plastic containers. A preferred
`container for an ophthalmic product is a low-density polyeth-
`ylene container that has been sterilized using ethylene oxide
`instead of gamma-irradiation. A preferred container for a
`nasal product
`is a high-density polyethylene container
`equipped with a nasal spray pump.
`[0067] The references cited herein, to the extent that they
`provide exemplary procedural or other details supplementary
`to those set forth herein, are specifically incorporated by
`reference.
`
`[0068] Unless otherwise required by context, singular
`terms used herein shall include pluralities and plural terms
`shall include the singular.
`
`EXAMPLES
`
`[0069] The following examples, including the experiments
`conducted and results achieved are provided for illustrative
`purposes only and are not to be construed as limiting the
`invention.
`
`Example 1
`
`Olopatadine-PDE4 Inhibitor Solubility Study
`
`[0070] The following experiments were conducted to deter-
`mine the effect of compounds of Formula I on the aqueous
`solubility of olopatadine.
`[0071]
`Formulations with the compositions shown in Table
`1 were prepared for olopatadine solubility testing as follows:
`ten milliliter samples of the formulations containing either
`0%, 0.1%, 0.3%, or 1% ofeither Compound 1 (4-(3,5-Dichlo-
`ropyridin-4-ylamino)-7-methoxy-8-(6-(4-methylpiperazin-
`1-yl)hexyloxy)quinolin-2(1H)-one) or Compound 2 (4-(3,5-
`Dichloropyridin-4-ylamino)-7-methoxy-8-(6-
`morpholinohexyloxy)quinolin-2(1H)-one) with at least 1%
`Olopatadine Hydrochloride as shown in Table 2 were pre-
`pared and adjusted to the target pH. Compound 2 was not
`tested at pH 7.4 as

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket